Picard Medical (PMI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Jul, 2026Executive summary
Annual Meeting scheduled for July 17, 2026, at 3:00 p.m. Mountain Time, to be held virtually.
Proxy Supplement corrects voting options for the advisory vote on executive compensation frequency and updates Audit Committee membership disclosure.
Stockholders can vote electronically, by mail, or during the virtual meeting using a control number.
Voting matters and shareholder proposals
Election of four directors to serve until the 2027 annual meeting.
Advisory vote on the compensation of named executive officers.
Advisory vote on the frequency of future say-on-pay votes, with options for 1, 2, or 3 years.
Proposal to amend the Certificate of Incorporation for a reverse stock split at a ratio of 1-for-15 to 1-for-50.
Proposal to designate a new Class B common stock with 20 votes per share.
Ratification of MaloneBailey LLP as the independent registered public accounting firm for 2026.
Board of directors and corporate governance
Four nominees for director positions: Richard Fang, Sam Van, Joe Xiao, and George Ye.
Board recommends a vote "FOR" all proposals.
Latest events from Picard Medical
- Key proposals include director elections, reverse stock split, and creation of high-vote Class B stock.PMI
Proxy filing29 Jun 2026 - Proxy seeks approval for director elections, reverse split, new Class B stock, and auditor ratification.PMI
Proxy filing15 Jun 2026 - Q1 2026 revenue jumped 85% to $1.2M, but losses and NYSE compliance risks persist.PMI
Q1 202621 May 2026 - Only FDA-approved total artificial heart maker, but faces ongoing losses and regulatory risks.PMI
Registration filing20 May 2026 - Sole FDA-approved TAH provider seeks $9.1M to fund next-gen heart tech and global expansion.PMI
Registration filing1 May 2026 - IPO seeks $9.1M to fund artificial heart innovation amid ongoing losses and regulatory risks.PMI
Registration filing27 Apr 2026 - Revenue up 12.5% to $4.94M, IPO raised $35.5M, cash improved, net loss $(27.0)M.PMI
Q4 202525 Mar 2026 - Approval sought for major share increase and new issuances to enable financing and NYSE compliance.PMI
Proxy Filing19 Feb 2026 - Vote proposed to double authorized common stock, supporting future capital needs and flexibility.PMI
Proxy Filing19 Feb 2026